Latest Nanexa News & Updates

See the latest news and media coverage for Nanexa. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nanexa

Developer of long-acting injectable drug delivery systems

nanexa.com
Headquarters
Uppsala, Sweden
Founded year
2007
Company type
Public company
Number of employees
25–50

Last updated

Latest news about Nanexa

In short: Nanexa secured a major $500M licensing deal with Moderna and reported strong preclinical results for its long-acting semaglutide formulations.

Company announcements

  • Nanexa

    Nanexa publishes interim report for January-March 2026

    Reports strong preclinical results for semaglutide formulations, financials show turnover TSEK 1,632 and cash TSEK 73,022. All warrants exercised, yielding SEK 55.7 million.

  • Nanexa

    Nanexa resolves on set-off of SEK 20 million loan

    The Board issues shares and warrants to lenders, converting debt to equity, strengthening the balance sheet and preserving liquidity. Dilution is approximately 3.27% from shares and up to 6.34% total.

  • Nanexa

    Nanexa issues notice of annual general meeting

    The meeting occurs on 12 May 2026 at 3:00 pm in Uppsala, Sweden. Shareholders must register by 7 May 2026. Agenda includes financial statements, board elections, and share issue authorizations.

  • Nanexa

    Nanexa announces exercise of warrants

    All 27,878,788 warrants exercised for 27,878,788 new shares at SEK 2 each, raising SEK 55.7 million before costs. Shares increase to 184,786,535.

Unlock all announcements with a

Media coverage

  • FinanzNachrichten

    Nanexa AB: Nanexa publishes interim report for January-March 2026

    Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide Significant events during the first quarter of 2026In January, Nanexa announced...

  • London Stock Exchange

    Nanexa publishes annual report for 2025

    Nanexa AB (publ) today announces that the Annual Report for 2025 has been published and is available on the company's website Nanexa AB - Financial...

  • Dagens industri

    Nanexa turns operating result from minus to plus

    Drug-delivery company Nanexa reports an operating result of 16.7 million kronor (minus 12.0) in the fourth quarter of 2025.

  • London Stock Exchange

    Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

    Nanexa's atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate many common side effects...

Unlock all articles with a

Never miss news about Nanexa

Track Nanexa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nanexa competitors & trending companies

Browse news for competitors to Nanexa and other trending companies.